Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury
© BioMed Central Ltd 2010
Published: 20 October 2010
Previously in this journal, we published a phase 1 study of nebulized heparin in patients with acute lung injury . Patients were administered heparin at doses of 50,000, 100,000, 200,000, or 400,000 U/day for 2 days, and bronchoalveolar lavage (BAL) fluid samples were taken at baseline and after the last heparin dose. The study demonstrated a trend to reduced coagulation activation (prothrombin fragments) in BAL fluid after the last dose of nebulized heparin .
Following publication of these data, we were offered the possibility of further analysis of the BAL fluid with additional markers of coagulation activation, including thrombin-antithrombin complexes (TATcs), fibrin degradation products (FDPs), and plasminogen activator activity (PAI-1) levels. We wish to publish the results of this further analysis. The 400,000 U/day group had one patient more than the same group in the previously published data.
fibrin degradation product
plasminogen activator activity
- Dixon B, Santamaria JD, Campbell DJ: A phase 1 trial of nebulised heparin in acute lung injury. Crit Care. 2008, 12: R64-10.1186/cc6894.PubMed CentralView ArticlePubMed
- Dixon B: The role of microvascular thrombosis in sepsis. Anaesth Intensive Care. 2004, 32: 619-629.PubMed
- Blaisdell FW: Pathophysiology of the respiratory distress syndrome. Arch Surg. 1974, 108: 44-49.View ArticlePubMed